TUNGKOL SA EPISODE NA ITO
In this interview, discover discuss key findings from the DESTINY-Breast09 trial and their implications for clinical practice, including practical advice for oncologists exploring treatment sequencing strategies with T-DXd.
Ingles
Estados Unidos
KOPYA NG SALIN 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
I-SEARCH ANG MGA NAKARAANG EPISODE
I-search ang mga nakaraang episode ng Taylor & Francis.
IBA PANG MGA EPISOD SA PODCAST NA ITO
First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study by Taylor & Francis Group
This podcast features two of the investigators from the international, randomized, Phase III EMBARK trial (NCT02319837) in conversation.
EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as compared with androgen deprivation t…
This podcast focuses on the real-world implications of these EMBARK findings for clinical practice.
In this podcast episode, the speakers discuss how the findings from the EMBARK clinical trial could translate into real world practice.
Paunawa: Ang podcast at artwork na naka-embed sa page na ito ay mula sa Taylor & Francis Group, na pag-aari ng may-ari nito at hindi kaakibat o ineendorso ng Listen Notes, Inc.
I-EDIT
Salamat sa pagtulong na mapanatiling naka-update ang database ng podcast.
